diphencyprone Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Diphenylcyclopropenone (diphencyprone) is a topically administered experimental drug intended for treating alopecia areata and alopecia totalis. Topical immunotherapy using diphenylcyclopropenone may also be an effective treatment option for recalcitrant warts. It is not approved by either the Food and Drug Administration or the European Medicines Agency.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

2,3-diphenyl-2-cyclopropen-1-one | diphencyprone | diphenylcyclopropenone | diphenylcyclopropenone monohydrate | dpcp

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Alopecia Areata

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Alopecia Areata (Phase 3)

Human papillomavirus 16 (Phase 2)

Hypersensitivity, Delayed (Phase 1)

Immunosuppression Therapy (Phase 1)

Melanoma (Phase 1)

Neoplasm Metastasis (Phase 1)

Pharmacokinetics (Phase 1)

Ultraviolet Rays (Phase 1)

Vitiligo (Phase 4)

Warts (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue